Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) EPS (Weighted Average and Diluted) (2016 - 2025)

Sanofi's EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$2.34 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 1551.33% to -$2.34 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.34, a 1551.33% decrease, with the full-year FY2025 number at $7.41, up 56.64% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$2.34 in Q4 2025 for Sanofi, down from $1132.6 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for SNY hit a ceiling of $1132.6 in Q2 2025 and a floor of -$2.34 in Q4 2025.
  • Historically, EPS (Weighted Average and Diluted) has averaged $355.14 across 5 years, with a median of $17.23 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 4522.73% in 2022 and later crashed 1551.33% in 2025.
  • Tracing SNY's EPS (Weighted Average and Diluted) over 5 years: stood at $0.2 in 2021, then soared by 4522.73% to $9.32 in 2022, then tumbled by 103.75% to -$0.35 in 2023, then skyrocketed by 59.44% to -$0.14 in 2024, then crashed by 1551.33% to -$2.34 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SNY at -$2.34 in Q4 2025, $1132.6 in Q2 2025, and -$0.14 in Q4 2024.